Literature DB >> 2838442

Randomized neutron dose searching study for malignant gliomas of the brain: results of an RTOG study. Radiation Therapy Oncology Group.

G E Laramore1, M Diener-West, T W Griffin, J S Nelson, M L Griem, F J Thomas, F R Hendrickson, B R Griffin, L C Myrianthopoulos, J Saxton.   

Abstract

From September 1980 through January 1985, the Radiation Therapy Oncology Group (RTOG) conducted a randomized, dose-searching study testing the efficacy of a concomitant neutron boost along with whole brain photon irradiation in the treatment of malignant gliomas of the brain. Patients had to have biopsy-proven, supratentorial, anaplastic astrocytoma or glioblastoma multiforme (Nelson schema) to be eligible for the study. The whole brain photon irradiation was given at 1.5 Gy per treatment, 5 days-a-week to a total dose of 45 Gy. Two days-a-week the patients were to receive neutron boost irradiation to the tumor volume as determined on CT scans. The neutron irradiation was to be given prior to and within 3 hours of the photon irradiation on that day. The rationale for this particular treatment regime is discussed. A total of 190 evaluable patients were randomized among 6 different neutron dose levels: 3.6, 4.2, 4.8, 5.2, 5.6 and 6.0 Gyn gamma. There was no difference in overall survival among the 6 different dose levels, but for patients having less aggressive tumor histology (anaplastic astrocytoma), there was a suggestion that patients on the higher dose levels had poorer overall survival than patients on the lower dose levels and also did worse than historical photon controls. Important prognostic factors were identified using a Cox stepwise regression analysis. Tumor histology, Karnofsky performance status, and patient age were found to be related to survival while extent of surgery and neutron dose had no significant impact. Autopsies were performed on 35 patients and the results correlated with the actual neutron dose as determined by central-axis isodose calculations. At all dose levels there were some patients with both radiation damage to normal brain tissue and evidence of viable tumor. No evidence was found for a therapeutic window using this particular treatment regimen.

Entities:  

Mesh:

Year:  1988        PMID: 2838442     DOI: 10.1016/0360-3016(88)90384-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Boron neutron capture enhancement (BNCE) of fast neutron irradiation for glioblastoma: increase of thermal neutron flux with heavy material collimation, a theoretical evaluation.

Authors:  P Paquis; J P Pignol; M Lonjon; N Brassart; A Courdi; P Chauvel; P Grellier; M Chatel
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 2.  Common challenges and problems in clinical trials of boron neutron capture therapy of brain tumors.

Authors:  N Gupta; R A Gahbauer; T E Blue; B Albertson
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

Review 3.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

Review 4.  The rationale and requirements for the development of boron neutron capture therapy of brain tumors.

Authors:  A H Soloway; R F Barth; R A Gahbauer; T E Blue; J H Goodman
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

5.  Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

Authors:  Keith J Stelzer; James G Douglas; David A Mankoff; Daniel L Silbergeld; Kenneth A Krohn; George E Laramore; Alexander M Spence
Journal:  Neuro Oncol       Date:  2007-11-30       Impact factor: 12.300

Review 6.  Back to the future--radiotherapy in high grade gliomas.

Authors:  M Brada
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.